Translational medicine is enhancing a new route to develop in the Tissue Engineering for Regeneration of organs which is fed with Medical products. A new technology is emerged in humans currently working on clinical testing for a variety of medical needs involving tissue and organ regeneration. These involve the Safety evaluation of 3 established product paradigms: pharmaceuticals such biologically active substances, transplantation which may be cells or tissue, and devices such as biomaterials. This product can recapitulate organ or tissue structure and function with unique biological activity and characteristics, they require new preclinical paradigms to bring products to clinical trials. Establishing product safety programs requires broad-based knowledge of tissue and organ homeostasis, regenerative biology and Translational medicine to design new preclinical paradigms.
Therefore, toxic pathology study has as compelling scientific role in evaluating product, which characterizes responses in tissue and distinguish optimal help as regeneration from deficient or partial outputs which is an indicative of substandard functionality to repair. As new-tissue engineering and regenerative medical technologies develop for tissue and organ regeneration, the toxic pathologist will be asked to develop novel testing, to reevaluate established toxic diagnostic criteria and reinterpret tissue responses that may extend beyond present standards.